All eyes have been on Ranbaxy Laboratories' stumbles over its generic Lipitor manufacturing, overshadowing projects elsewhere that have added to the manufacturing footprint for the Indian generic drugmaker.
During its earnings discussions this week, executives emphasized that it has fixed the problems that led to recalls and a production halt of its Atorvastatin after glass particles were found in the API. It is again producing the API in India and the finished product in the U.S.
But in the course of the year, it has made manufacturing strides elsewhere. It said in its earnings report that it has "established a new manufacturing base in Morocco" for a business drive in North Africa. It has also opened a plant on a greenfield site in Malaysia that it says "will significantly enhance the existing manufacturing capacity" to broaden its reach in Asia.
The $40 million plant in Malaysia is its second there. The facility will make tablets and capsules, primarily for cardiovascular, antidiabetic, anti-infective and gastrointestinal treatments. It has said that the new plant will increase its output in that country to three billion doses annually from one billion today.
- here's the earnings release
Manufacturing continues to undercut Ranbaxy
Ranbaxy building second plant in Malaysia
Ranbaxy to make drugs in Malaysia, Nigeria